Los Angeles, Calif. – September 21, 2018 – After only two years, L-Nutra’s flagship product, ProLon®, the first-ever five-day Fasting Mimicking Diet® (FMD®), is currently the only product in healthcare that is designed, researched, tested and now patented for optimizing Longevity and Healthspan.
ProLon launched in the United States on September 21, 2016, and quickly expanded into 12 international countries. Today, ProLon has globally impacted the lives of 80,000 consumers in the United States and Europe. L-Nutra will be expanding into Canada, Mexico, Australia, New Zealand, Middle East, Japan and China. The company is on track to be one of the fastest growing nutri-technology companies with breakthrough scientific research and a rich pipeline of fasting mimicking diets.
“We are at a very exciting time in the history of Public Health whereby we have scientifically identified many health benefits of fasting, a practice that has been part of the human race since its existence on Earth and that was abandoned by many in the last 100 years, only to witness a major increase in chronic diseases. L-Nutra makes fasting safe, practical and effective with a natural food regimen that mimics its benefits. We launched the new fasting category in nutrition and gained the trust of both healthcare practitioners and consumers”, said Joseph Antoun MD, CEO of L-Nutra. “We know we have a very effective and successful product when we sign up around 90 new health clinics per week and generate 40% of our consumer sales from friends and family of existing customers”.
The main health benefits of the Fasting Mimicking Diet are due to the metabolic and cellular effects of the diet. While most diets focus on weight loss, the Fasting Mimicking Diet not only induces weight loss but also maintains healthy levels of cholesterol, triglycerides, blood sugar and other important health markers. Due to these effects, the Fasting Mimicking Diet was granted the first patent in history on promoting tissue/organ regeneration, Longevity and Healthspan July 10th, 2018. The FMD holds multiple patents discovered and clinically tested by the laboratory of Valter Longo and Keck Hospital at the University of Southern California (USC). These patents are exclusively licensed to L-Nutra and include indications such as cancer, auto-immune diseases, diabetes, and cardiovascular diseases. USC and multiple research centers around the world are currently researching the impact of the FMD on these diseases.
ProLon has helped over 80,000 individuals to improve their wellbeing. More than 5,500 healthcare providers have recommended ProLon to their patients. “Our goal is to scientifically uncover all the health benefits of fasting and make them available to billions of individuals,” says Dr. Antoun. “We are aiming at enhancing human longevity by many years, and we believe it is within in our reach,” continued Dr. Antoun.
As part of the commitment of the company to help improve the health of others, ProLon inventor, Dr. Valter Longo, generously donates all profits from his 60% share in L-Nutra to the Create Cures Foundation, whose mission is to help fund ways to prevent illness and promote longer, healthier lives.